| 0.4661 -0.003 (-0.62%) | 05-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.56 | 1-year : | 0.6 |
| Resists | First : | 0.48 | Second : | 0.52 |
| Pivot price | 0.45 |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.45  |
MA(20) : | 0.46 |
| MA(100) : | 0.52 |
MA(250) : | 0.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 32.3 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 2.26 | Low : | 0.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SCNI ] has closed below upper band by 35.7%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.48 - 0.48 | 0.48 - 0.48 |
| Low: | 0.44 - 0.44 | 0.44 - 0.44 |
| Close: | 0.46 - 0.47 | 0.47 - 0.47 |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Tue, 16 Apr 2024
Scinai Targets IL-17 in Psoriasis Drug Development - TipRanks.com - TipRanks
Wed, 10 Apr 2024
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development ... - BioSpace
Mon, 08 Apr 2024
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP ... - PR Newswire
Tue, 12 Mar 2024
Scinai leadership to attend BIO-Europe Spring 2024 - Morningstar
Tue, 13 Feb 2024
Scinai Welcomes Liat Halpert as Head of Business Development and Sales - BioSpace
Thu, 25 Jan 2024
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet ... - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 1,020 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | -4.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.37 |
| Qtrly Earnings Growth | 25.8 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|